Skip to content

Expression of TIM-3 on Lymphocytes in Sepsis

Expression and the Clinical Significance of TIM-3 on Lymphocytes During Sepsis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02319876
Enrollment
80
Registered
2014-12-18
Start date
2014-02-28
Completion date
2015-12-31
Last updated
2015-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression, Sepsis

Brief summary

The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its role in immunosuppression during sepsis.

Detailed description

Immunosuppression is the leading cause of death in septic patients.Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of sepsis. Previous studies indicated that T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein and was identified as a marker of lymphocyte dysfunction. The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its further role in immunosuppression during sepsis.

Interventions

None listed

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* patients with severe sepsis * patients undergo invasive spine surgery * healthy volunteers

Exclusion criteria

* patients with immunodeficient diseases * patients who accept glucocorticoid or immunosuppressant * patients with an age older than 18 years * patients providing the informed consent

Design outcomes

Primary

MeasureTime frameDescription
TIM-3 expression on CD4+, CD8+ T cells and CD14+ monocyteswithin 24h after recruitmentTIM-3 level on T cells was compared between different populations.

Secondary

MeasureTime frame
28-day mortality28 days after diagnosis of sepsis

Countries

China

Contacts

Primary ContactLulong Bo, M.D., Ph.D.
lulongbo@gmail.com+862131163489

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026